Epigenomics AG : Epigenomics Begins Trading on OTCQX Marketplace in the U.S.

10.01.2014

• BNY Mellon to act as Principal American Liaison (PAL) for Epigenomics on OTCQX
• Epigenomics' ADRs to start trading under ticker symbol EPGNY today

Berlin, Germany, and Germantown, MD, U.S.A., January 10, 2014 - Epigenomics AG (Frankfurt Prime Standard: ECX; OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company has been approved for trading on OTCQX.

Epigenomics' American Depositary Receipts (ADRs) began trading today on OTCQX International, a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies that are listed on a qualified international exchange, produce quarterly management reports and provide their home country disclosures to U.S. investors. BNY Mellon will act as the Company's PAL on OTCQX responsible for providing professional guidance on OTCQX requirements.

Dr. Thomas Taapken, CEO/CFO of Epigenomics, commented: "Raising our profile in the U.S. public capital markets is an important part of our strategy as we approach the decision by the FDA regarding the approval of our blood-based colorectal cancer detection test, Epi proColon®. We look forward to intensifying our interactions with U.S. capital markets participants and our sponsored ADR program also serves as the stepping stone to approach U.S. investors more efficiently in the future."

Epigenomics trades in the U.S. on OTCQX under the ticker symbol "EPGNY," where each ADR represents 5 ordinary shares. U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

- Ends -

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin
Tel. [phone]
[e-mail]
www.epigenomics.com  

For US press inquiries:

Epigenomics, Inc.
20271 Goldenrod lane, 2nd Floor
Germantown Md., 20874
[e-mail]

About Level 1 American Depositary Receipt (ADR) Program

Level 1 ADRs allow US investors to trade shares in the form of securities from companies that are not listed on a U.S. stock exchange. ADRs represent ordinary shares of a company at a certain ratio. Level 1 ADRs are traded on the OTCQX, OTCQB or OTC Pink marketplaces and are issued by the designated depositary bank that acts as the transfer agent, either in cooperation with the company (Sponsored) or without the company's involvement (Unsponsored). The price generally tracks the price of the foreign security in its home market, adjusted for the ratio of ADRs to foreign company shares.

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company's products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is under regulatory review by the FDA for the U.S.A. Additionally, the company markets its tissue assay for use in lung cancer diagnosis, Epi proLung®, in Europe. The Company's technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.